Primary Care-Based Follow-up of Cancer Survivors of the Prostate and Kidney

NCT06214000 | Completed

• 1 other identifier: 8500
• Study Type: observational
• Target: 178
• Locations: 1 country
• Sites: 1

Brief Summary

In France, the second cancer plan of 2009-2013 aimed to strengthen the role of MT by putting it back at the center of patient monitoring, in particular by asking "regional health agencies to encourage and support local experiments" which aim for better coordination between the city and the hospital. The third cancer plan for 2014-2019 insists on this measure because it had proven to be unproductive, and recommends, in addition to the creation of a nurse dedicated to the coordination of care between community medicine and the hospital, the creation of a direct telephone line to reach the hospital medical team. This measure is mainly aimed at the follow-up of certain cancers that do not require the technical support of the hospital, as is the case in the post-operative follow-up of RCC and CaP, where the additional examinations carried out during follow-up are carried out in the city. The research hypothesis is that this new method of monitoring had a positive impact on care in terms of quality, accessibility, organization and costs.

Conditions

Prostate Cancer; Kidney Cancer

Keywords

Prostate Cancer; kidney cancer

Outcome Measures

Primary Outcomes (1)

• Evaluation of the economic impact of the treatment of patients operated on for localized prostate or kidney cancer

  This study concerns a retrospective evaluation of the economic cost of treatment of localized prostate or kidney cancer in patients followed at the University Hospitals of Strasbourg during the period from January 1, 2015 to December 31, 2021.

  The period concerned is from January 1, 2015 to December 31, 2021.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult subjects (≥18 years old) operated on for localized prostate or kidney cancer during the period from 01/01/2015 to 12/31/2021

You may qualify if:

• Adult subjects (≥18 years old)
• Patient operated on for localized prostate or kidney cancer
• Patient followed at the HUS during the period from 01/01/2015 to 12/31/2021
• Subject who has not expressed his opposition, after information, to the reuse of his data for the purposes of this research.

You may not qualify if:

• Subject having expressed opposition to participating in the study
• Patient under active therapy (hormonotherapy, systemic treatment) for the pathology studied
• Impossibility of providing the subject with informed information (difficulties in understanding the subject, etc.)
• Subject under judicial protection
• Subjects under guardianship or curatorship

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service d'Urologie - CHU de Strasbourg - France

Strasbourg, 67091, France

Location

MeSH Terms

Conditions

Prostatic Neoplasms; Kidney Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Urologic Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Kidney Diseases; Urologic Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 11, 2023
• First Posted: January 19, 2024
• Study Start: December 20, 2021
• Primary Completion: June 21, 2022
• Study Completion: June 21, 2022
• Last Updated: March 13, 2024

Record last verified: 2023-12

Locations

FR (1)